Azacitidine/Lenalidomide

阿扎胞苷/来那度胺

Report date: 2025/05/14 14:37:06

Base Information

Drug NameAzacitidine/Lenalidomide
Drug Alias NameLenalidomide+Azacitidine来那度胺+阿扎胞苷阿扎胞苷+来那度胺Lenalidomide/AzacitidineAzacitidine+Lenalidomide +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analoguesSmall molecules > Molecular Glue
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitorsCereblon inhibitorsDNA-binding protein Ikaros degraders +[5] 
TargetsDNA (cytosine-5)-methyltransferase 1CereblonDNA-binding protein Ikaros +[5] 
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes AzacitidineLenalidomide
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelgene Corp
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A